RecruitingPhase 4NCT06484868
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Studying Acquired partial lipodystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amryt Pharma
- Intervention
- Metreleptin(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2024 – 2028
Study locations (12)
- Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France
- Hopital Pitie-Salpetriere, Paris, France
- Hôpital Saint-Antoine, Paris, France
- Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
- Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM), Berlin, Germany
- Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin, Ulm, Germany
- Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy
- Universitá degli Studi "Magna Graecia" di Catanzaro, Catanzaro, Italy
- Azienda Ospedaliero Universitaria Maggiore della Carità di Novara, Novara, Italy
- Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello, Pisa, Italy
- A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia, Udine, Italy
- Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital, Cambridge, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06484868 on ClinicalTrials.govOther trials for Acquired partial lipodystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07516496Metabolic Phenotyping in vEDSCambridge University Hospitals NHS Foundation Trust
- RECRUITINGNCT05996536Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- RECRUITINGPHASE2NCT05470504Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin ResistanceNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- ACTIVE NOT RECRUITINGPHASE3NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLAmryt Pharma
- RECRUITINGNANCT03900286Low Energy Diet and Familial Partial LipodystrophyCambridge University Hospitals NHS Foundation Trust
- ACTIVE NOT RECRUITINGPHASE2NCT02262806Compassionate Use of Metreleptin in Previously Treated People With Partial LipodystrophyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)